These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34126248)

  • 21. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
    Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of 12 weeks of treatment with intravenously administered bococizumab, a humanized monoclonal antibody blocking proprotein convertase subtilisin/kexin type 9, in hypercholesterolemic subjects on high-dose statin.
    Fazio S; Robertson DG; Joh T; Wan H; Riel T; Forgues P; Baum CM; Garzone PD; Gumbiner B
    Cardiovasc Ther; 2018 Feb; 36(1):. PubMed ID: 29057618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cardiovascular Outcomes and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: Current Data and Future Prospects.
    Duprez DA; Handelsman Y; Koren M
    Vasc Health Risk Manag; 2020; 16():403-418. PubMed ID: 33116551
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Up to date lipid lowering treatment].
    Paragh G; Karádi I
    Orv Hetil; 2016 Jul; 157(31):1219-23. PubMed ID: 27476517
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trends in the Utilization of Lipid-Lowering Medications in Australia: An Analysis of National Pharmacy Claims Data.
    Talic S; Marquina Hernandez C; Ofori-Asenso R; Liew D; Owen A; Petrova M; Lybrand S; Thomson D; Ilomaki J; Ademi Z; Zomer E
    Curr Probl Cardiol; 2022 Jul; 47(7):100880. PubMed ID: 34108083
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Statins, Ezetimibe, and Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors to Reduce Low-Density Lipoprotein Cholesterol and Cardiovascular Events.
    O'Keefe JH; DiNicolantonio JJ; Lavie CJ
    Am J Cardiol; 2017 Feb; 119(4):565-571. PubMed ID: 28081940
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proprotein Convertase Subtilisin Kexin Type 9 Inhibition for Autosomal Recessive Hypercholesterolemia-Brief Report.
    Thedrez A; Sjouke B; Passard M; Prampart-Fauvet S; Guédon A; Croyal M; Dallinga-Thie G; Peter J; Blom D; Ciccarese M; Cefalù AB; Pisciotta L; Santos RD; Averna M; Raal F; Pintus P; Cossu M; Hovingh K; Lambert G
    Arterioscler Thromb Vasc Biol; 2016 Aug; 36(8):1647-50. PubMed ID: 27079874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current update on PCKS9 inhibitors].
    Gencer B; Nanchen D; Collet TH; Rodondi N; Mach F
    Rev Med Suisse; 2018 Feb; 14(596):482-486. PubMed ID: 29489129
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The New Face of Hyperlipidemia Management: Proprotein Convertase Subtilisin/Kexin Inhibitors (PCSK-9) and Their Emergent Role As An Alternative To Statin Therapy.
    Smith L; Mosley J; Yates J; Caswell L
    J Pharm Pharm Sci; 2016; 19(1):137-46. PubMed ID: 27096698
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of statin therapy on plasma proprotein convertase subtilisin kexin 9 (PCSK9) concentrations: a systematic review and meta-analysis of clinical trials.
    Sahebkar A; Simental-Mendía LE; Guerrero-Romero F; Golledge J; Watts GF
    Diabetes Obes Metab; 2015 Nov; 17(11):1042-55. PubMed ID: 26183252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inclisiran Durably Lowers Low-Density Lipoprotein Cholesterol and Proprotein Convertase Subtilisin/Kexin Type 9 Expression in Homozygous Familial Hypercholesterolemia: The ORION-2 Pilot Study.
    Hovingh GK; Lepor NE; Kallend D; Stoekenbroek RM; Wijngaard PLJ; Raal FJ
    Circulation; 2020 Jun; 141(22):1829-1831. PubMed ID: 32479195
    [No Abstract]   [Full Text] [Related]  

  • 32. Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis.
    Matta A; Bongard V; Bouisset F; Taraszkiewicz D; Rabès JP; Ferrières J
    Med Sci Monit; 2021 May; 27():e928784. PubMed ID: 33958572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characteristics and Outcomes of Patients Treated With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (The Mayo Clinic Experience).
    Oren O; Kludtke EL; Kopecky SL
    Am J Cardiol; 2019 Dec; 124(11):1669-1673. PubMed ID: 31740018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [PCSK9 inhibitors. A new approach for treatment of hypercholesterolemia].
    Saußele T
    Med Monatsschr Pharm; 2015 Jul; 38(7):250-7. PubMed ID: 26364362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors to treat hypercholesterolemia: Effect on stroke risk.
    Milionis H; Barkas F; Ntaios G; Papavasileiou V; Vemmos K; Michel P; Elisaf M
    Eur J Intern Med; 2016 Oct; 34():54-57. PubMed ID: 27363304
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
    Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Statins, plasma proprotein convertase subtilisin/kexin type 9 concentrations, and LDL lowering.
    Khera A
    Clin Chem; 2012 Jan; 58(1):6-7. PubMed ID: 22110017
    [No Abstract]   [Full Text] [Related]  

  • 38. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial.
    Raal F; Scott R; Somaratne R; Bridges I; Li G; Wasserman SM; Stein EA
    Circulation; 2012 Nov; 126(20):2408-17. PubMed ID: 23129602
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
    Shimada YJ; Cannon CP
    Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes.
    Khan SU; Talluri S; Riaz H; Rahman H; Nasir F; Bin Riaz I; Sattur S; Ahmed H; Kaluski E; Krasuski R
    Eur J Prev Cardiol; 2018 May; 25(8):844-853. PubMed ID: 29569492
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.